Navigation Links
LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
Date:11/7/2007

BURLINGTON, Mass., Nov. 7 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), which develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease, is scheduled to participate at the Canaccord Adams inaugural Cardiovascular Conference on Tuesday, November 13, 2007, in New York City, NY at the Waldorf-Astoria Hotel.

David B. Roberts, President of LeMaitre Vascular, will provide an update on the company at 3:45 pm Eastern Standard Time.

A live audio webcast of the presentation will be available via the Internet at http://www.lemaitre.com/investor and will be available for replay for 30 days.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures and markets medical devices and implants for the treatment of peripheral vascular disease. The Company's principal executive offices are located at 63 Second Avenue, Burlington, Massachusetts 01803. Additional information can be found at http://www.lemaitre.com.


'/>"/>
SOURCE LeMaitre Vascular, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. LeMaitre Vascular to Start Italian Sales Force
2. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
3. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:183 New Medicines in Development for Diabetes 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 2Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 3Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 4Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site 5Avandia Raises Heart Failure Risk More Than Actos 54807 1Avandia Raises Heart Failure Risk More Than Actos 54807 2Avandia Raises Heart Failure Risk More Than Actos 54807 3Veteran Rehab Specialist Rafael Ibarra Joins Alliance Seating 26 Mobility in Georgia 54804 1Veteran Rehab Specialist Rafael Ibarra Joins Alliance Seating 26 Mobility in Georgia 54804 2Synch Solutions Named to Inc Magazines 2009 Ranking of the Fastest Growing Companies in the United States 54801 1Synch Solutions Named to Inc Magazines 2009 Ranking of the Fastest Growing Companies in the United States 54801 2